Access to Cannabis-based Products for Medicinal Use

The motion

That the Parliament welcomes the Home Office’s rescheduling of certain cannabis-based products for medicinal use (CBPMs) in 2018; notes the reported improvement in some children with treatment resistant epilepsy who take CBPMs, such as Cole Thomson, from East Kilbride, who it understands receives Bedrolite on private prescription; acknowledges the reported financial pressure that these prescriptions can place on families; further acknowledges the reported hesitancy of NHS consultants to prescribe unlicensed CBPMs due to the lack of robust evidence; notes the view that the rescheduling does not go far enough in assisting some patients, and the calls for a change in rules to allow GPs, who consider it appropriate, to prescribe unlicensed CBPMs where a non-NHS consultant has initiated that course of treatment; understands that the British Paediatric Neurology Association published its updated Guidance on the use of cannabis-based products for medicinal use in children and young people with epilepsy in October 2021, which, it considers, outlines concerns around the lack of randomised control trials demonstrating a product’s safety, quality and efficacy; acknowledges the Scottish Government’s reported commitment to collaborate with NHS England and the National Institute for Health Research to support research trials into medicinal cannabis in order to give NHS consultants the assurances that they need to consider prescribing CBPMs on the NHS; understands that, once a medicinal product has undergone clinical trials, it could be considered by the Medicines and Healthcare products Regulatory Agency for licensing and that this could lead to further consideration by organisations such as the National Institute for Health and Care Excellence, the Scottish Medicines Consortium and NHS Scotland; notes the calls for industry to run observational and clinical trials; believes that an increased evidence base offers the best opportunities for expansion of the range of CBPMs available from the NHS; welcomes the reported plans by Target Healthcare, which operates in East Kilbride, to produce CBPMs in Scotland, and notes the calls on the Scottish and UK governments to work together to find solutions on these issues.

No recorded vote on this motion. Most motions are never debated, and many that are debated are agreed without a division. Vote records are published from 2011.

SNP 11 Lab 4

Party shown is each supporter’s party when the motion was published.

1. 1 Jun 2022
   Cannabis-based Products for Medicinal Use

   Annabelle Ewing SNP Meeting of the Parliament

   The final item of business is a members’ business debate on motion S6M-03233, in the name of Collette Stevenson, on access to cannabis-based products for medicinal use. The debate will be concluded without any question being put. Motion de…